Company / CapEx per Share
Myriad Genetics, Inc. CapEx per Share History
FY2016-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest CapEx per Share
$0.62
FY2022
5-year range
$0.25 / $0.62
FY2018-FY2022
Trend
+141.7%
vs FY2021
Sector context
#21 of 192
Health Care
What the data says
Myriad Genetics, Inc.'s capex per share of $0.62 is higher than 89% of companies in the Health Care sector (FY2022). CapEx per Share has increased for 3 consecutive years, from $0.09 in FY2019 to $0.62 in FY2022.
Based on SEC 10-K filings.
0.62 in FY2022 with a 5-year CAGR of +49.3%. Top quartile in the Health Care sector.
Improved from $0.15 to $0.62 over the past 2 years.
Health Care sector context is included.
CapEx per Share over time
Growth rates
- 3-Year CAGR
- +91.1%
- 5-Year CAGR
- +49.3%
- 10-Year CAGR
- -
Sector benchmark
Top 11% in Health CareTop 11% of 192This company $0.62 Sector average $2.46
▼
-75.0% below sector average
Key checks
Key Insights
- Myriad Genetics, Inc.'s capex per share has grown for 3 consecutive years.
- In FY2022, capex per share increased 141.7% year-over-year.
- Ranks #21 out of 192 companies in the Health Care sector.
- Lowest capex per share in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score -1.23 (distress zone, below 1.8 threshold)
- Negative profit margin: -15.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | CapEx per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | $0.62 | +141.7% |
| FY2021 | $0.25 | +71.0% |
| FY2020 | $0.15 | +68.9% |
| FY2019 | $0.09 | -27.6% |
| FY2018 | $0.12 | +46.9% |
| FY2017 | $0.08 | +33.8% |
| FY2016 | $0.06 | -78.6% |
As of FY2022 · SEC 10-K · Updated Jun 30, 2026